2 completed, 1 active not recruiting, 1 withdrawn. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Active not recruiting 1, Withdrawn 1 |
Follow Sulindac: new trials by email Literature Review of Sulindac trials Research Report on Sulindac
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP) Eflornithine, Eflornithine Placebo, Sulindac 150 MG - Familial Adenomatous Polyposis | Phase 3 | Completed | Cancer Prevention Pharmaceuticals, Inc. | 171 | 2013-10-01 | 2021-06-08 |
| S0820, Adenoma and Second Primary Prevention Trial Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac - Colorectal Neoplasms | Phase 3 | Active not recruiting | SWOG Cancer Research Network | 354 | 2013-08-23 | 2026-10-23 |
| A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP) Eflornithine plus Sulindac, Eflornithine plus Placebo, Sulindac plus Placebo - Familial Adenomatous Polyposis | Phase 3 | Withdrawn | Cancer Prevention Pharmaceuticals, Inc. | 2011-03-01 | 2015-04-24 | |
| Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps placebo, eflornithine, sulindac - Precancerous Condition | Phase 3 | Completed | National Cancer Institute (NCI) | 375 | 1998-07-01 | 2015-01-22 |
Adenomatous Polyposis Coli (2) · Colonic Polyps (1) · Colorectal Neoplasms (1) · Precancerous Conditions (1)
Cancer Prevention Pharmaceuticals, Inc. (2) · National Cancer Institute (NCI) (1) · SWOG Cancer Research Network (1)
United States (3) · Belgium (1) · Canada (1) · Germany (1) · Netherlands (1) · Spain (1) · United Kingdom (1)
Alfred M. Cohen, M.D. (1) · Carol Burke, M.D. (1) · Frank Meyskens (1) · James Church, M.D. (1) · Jason A. Zell, D.O., MPH (1)
PMID 20538001, PMID 32905675, PMID 34261858
R01CA088078 (1), U10CA037429 (1)